Ambrx

About:

Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.

Website: http://www.ambrx.com

Top Investors: BlackRock, Fidelity, Cormorant Asset Management, Invus, Fosun Pharma

Description:

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.